Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
Department of Radiation Oncology, Triemlispital, Zürich, Switzerland; Inselspital, University Hospital Bern, Bern, Switzerland.
Clin Oncol (R Coll Radiol). 2021 Dec;33(12):e578-e585. doi: 10.1016/j.clon.2021.07.012. Epub 2021 Jul 31.
Sacral chordomas are locally aggressive, radio-resistant tumours. Proton therapy has the potential to deliver high radiation doses, which may improve the therapeutic ratio when compared with conventional radiotherapy. We assessed tumour control and radiation-induced toxicity in a cohort of sacral chordoma patients treated with definitive or postoperative pencil beam scanning proton therapy.
Sixty patients with histologically proven sacral chordoma treated between November 1997 and October 2018 at the Paul Scherrer Institute with postoperative (n = 50) or definitive proton therapy (n = 10) were retrospectively analysed. Only 10 (17%) patients received combined photon radiotherapy and proton therapy. Survival rates were calculated using the Kaplan-Meier actuarial method. The Log-rank test was used to compare different functions for local control, freedom from distant recurrence and overall survival. Acute and late toxicity were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
The median follow-up was 48 months (range 4-186). Local recurrence occurred in 20 (33%) patients. The 4-year local control, freedom from distant recurrence and overall survival rates were 77%, 89% and 85%, respectively. On univariate analysis, subtotal resection/biopsy (P = 0.02), tumour extension restricted to bone (P = 0.01) and gross tumour volume >130 ml (P = 0.04) were significant predictors for local recurrence. On multivariate analysis, tumour extension restricted to bone (P = 0.004) and gross total resection (P = 0.02) remained independent favourable prognostic factors for local recurrence. Twenty-four (40%), 28 (47%) and eight (11%) patients experienced acute grade 1, 2 and 3 toxicities, respectively. The 4-year late toxicity-free survival was 91%. Two patients developed secondary malignancies to the bladder 3-7 years after proton therapy.
Our data indicate that pencil beam scanning proton therapy for sacral chordomas is both safe and effective. Gross total resection, tumour volume <130 ml and tumour restricted to the bone are favourable prognostic factors for local tumour control.
骶骨脊索瘤是局部侵袭性、放射抗拒性肿瘤。质子治疗有潜力提供高剂量辐射,与传统放疗相比,这可能改善治疗效果。我们评估了在接受根治性或术后笔形扫描质子治疗的骶骨脊索瘤患者队列中肿瘤控制和放射诱导毒性。
1997 年 11 月至 2018 年 10 月期间,在保罗谢勒研究所接受术后(n=50)或根治性质子治疗(n=10)的 60 例组织学证实的骶骨脊索瘤患者进行回顾性分析。只有 10 例(17%)患者接受了光子放疗联合质子治疗。采用 Kaplan-Meier actuarial 法计算生存率。对数秩检验用于比较局部控制、远处无复发生存和总体生存的不同功能。根据常见不良事件术语标准(CTCAE)v5.0 评估急性和迟发性毒性。
中位随访时间为 48 个月(范围 4-186)。20 例(33%)患者发生局部复发。4 年局部控制、无远处复发和总生存率分别为 77%、89%和 85%。单因素分析显示,次全切除/活检(P=0.02)、肿瘤局限于骨(P=0.01)和大体肿瘤体积>130ml(P=0.04)是局部复发的显著预测因素。多因素分析显示,肿瘤局限于骨(P=0.004)和大体全切除(P=0.02)是局部复发的独立有利预后因素。24 例(40%)、28 例(47%)和 8 例(11%)患者分别发生急性 1、2 和 3 级毒性。4 年迟发性毒性无生存患者为 91%。2 例患者在质子治疗后 3-7 年发生膀胱继发性恶性肿瘤。
我们的数据表明,笔形扫描质子治疗骶骨脊索瘤安全有效。大体全切除、肿瘤体积<130ml 和肿瘤局限于骨是局部肿瘤控制的有利预后因素。